案例报告:免疫检查点抑制剂相关的肺高血压
Shanshan Yuan1, Xueqing Hu1, Yunquan Zhao1
1Department of Cardiology, Qingdao Municipal Hospital, Qingdao, Shandong, China.
Frontiers in cardiovascular medicine
|February 2, 2026
概括
免疫检查点抑制剂可以导致肺高血压 (PH),这是一个罕见但严重的副作用. 早期识别和组合治疗可能会改善这种危及生命的疾病患者的结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但可能会导致与免疫相关的不良事件.
- 肺高血压 (PH) 是与ICI治疗相关的罕见但严重的不良事件,与预后不佳有关.
- 由于其潜在的致命结果,ICI相关PH的认可正在增加.
研究的目的:
- 报告一个由编程细胞死亡蛋白1抑制剂tislelizumab引起的严重肺动脉高血压 (PAH) 病例.
- 突出三重组合向治疗对管理ICI相关的PAH的潜在好处.
主要方法:
- 一个65岁的男性患者接受了tislelizumab治疗的病例报告.
- 开始治疗PAH的三重组合治疗,包括macitentan,riociguat和treprostinil.
主要成果:
- 患者在治疗tislelizumab后出现严重的肺动脉高血压 (PAH).
- 在开始针对性PAH治疗后,观察到显著的临床改善.
结论:
- 与ICI相关的PH是一种罕见的,高度致命的并发症,没有确定的诊断或治疗指南.
- 进一步的病例报告和临床研究对于开发ICI相关PH的最佳管理策略至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
605
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
605
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
534
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
534
Pulmonary Hypertension: Classification and Pathogenesis
645
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
645
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
467
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
467
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
509
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
509
The Spindle Assembly Checkpoint
3.8K
The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.8K


